Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Antirheumatic Agents

Paclitaxel

Carboplatin

Hydroxychloroquine

Vaccines

Albumin-Bound Paclitaxel

Immunomodulating Agents

Interferons

Combination therapy with DCVAC and Standard of Care (Carboplatin, Paclitaxel)

Combination therapy with DCVAC, immune enhancers (Interferon-α, Hydroxychloroquine) and Standard of Care (Carboplatin, Paclitaxel)

Standard of Care chemotherapy (Carboplatin, Paclitaxel)

DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death

DCVAC add on to SOC

DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death

DCVAC and immune enhancers add on to SOC

SOC (Carboplatin, Paclitaxel): until progression or intolerance or death

Standard of Care Chemotherapy

Tomas Scheiner

The purpose of the study is to compare efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone in patients with stage IV NSCLC, as measured by progression free survival (PFS).

The purpose of the study is to compare efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. Standard of Care chemotherapy alone in patients with stage IV NSCLC, as measured by progression free survival (PFS).

Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer

A Phase I/II Study to Evaluate Safety and Efficacy of DCVAC/LuCa Added to Standard First Line ChT With Carboplatin and Paclitaxel +/- Immune Enhancers (Interferon-α and Hydroxychloroquine) vs ChT Alone in Patients With Stage IV NSCLC

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer	NCT02470468	Stage IV Non-sm...	DCVAC add on to... DCVAC and immun... Standard of Car...	18 Years -	Sotio Biotech Inc.
Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer	NCT02470468	Stage IV Non-sm...	DCVAC add on to... DCVAC and immun... Standard of Car...	18 Years -	Sotio Biotech Inc.
Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer	NCT02470468	Stage IV Non-sm...	DCVAC add on to... DCVAC and immun... Standard of Car...	18 Years -	Sotio Biotech Inc.

Spots Global Cancer Trial Database for dcvac add on to soc